Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Боль в спине: подбор терапии с точки зрения безопасности и эффективности
Боль в спине: подбор терапии с точки зрения безопасности и эффективности
Пилипович А.А. Боль в спине: подбор терапии с
точки зрения безопасности и эффективности. Consilium Medicum. 2017; 19 (2.3.
Неврология и Ревматология): 56–62. DOI: 10.26442/2075-1753_19.2.3.56-62
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Боль в спине (дорсалгия) – одна из самых частых патологий. Распространенность болей в нижней части спины достигает 40–80%. Боли в спине могут наблюдаться в клинической картине как неврологических, так и соматических заболеваний. Наиболее часто встречаются боли в спине невисцеральной природы. Они характерны для заболеваний костно-мышечной системы и соединительной ткани области позвоночного столба (дорсопатий). Лечение дорсалгии включает борьбу с острыми приступами болей и поддерживающее, профилактическое лечение в межприступный период. Чем раньше начато лечение и быстрее достигнут адекватный анальгетический эффект, тем меньше вероятность хронизации боли и лучше общий прогноз. Перспективным в плане терапии болевого синдрома является препарат группы селективных активаторов нейрональных калиевых каналов – флупиртин. За счет уникального механизма действия флупиртин открывает ряд дополнительных терапевтических возможностей и преимуществ: влияние на центральные механизмы боли и возможность предотвращения хронизации, миорелаксирующее действие в области боли, возможность нейропротекторного действия, отсутствие ряда характерных для опиоидов и нестероидных противовоспалительных препаратов побочных эффектов.
Ключевые слова: боль в спине, дегенеративные заболевания позвоночника, остеохондроз, дорсопатия, дорсалгия, флупиртин.
Key words: back pain, degenerative diseases of the spine, osteochondrosis, dorsopathy, dorsalgia, flupirtine.
Ключевые слова: боль в спине, дегенеративные заболевания позвоночника, остеохондроз, дорсопатия, дорсалгия, флупиртин.
________________________________________________
Key words: back pain, degenerative diseases of the spine, osteochondrosis, dorsopathy, dorsalgia, flupirtine.
Полный текст
Список литературы
1. Избранные лекции по неврологии II. Под ред. В.Л.Голубева. М.: МЕДпресс-информ, 2012; с. 180–92. / Izbrannye lektsii po nevrologii II. Pod red. V.L.Golubeva. M.: MEDpress-inform, 2012; s. 180–92. [in Russian]
2. Пилипович А.А. Болит спина – измени жизнь! Новая аптека. 2012; 11: 108–10. / Pilipovich A.A. Bolit spina – izmeni zhizn'! Novaia apteka. 2012; 11: 108–10. [in Russian]
3. Избранные лекции по неврологии. Под ред. В.Л.Голубева. М.: Эйдос Медиа, 2006; с. 224–43. / Izbrannye lektsii po nevrologii. Pod red. V.L.Golubeva. M.: Eidos Media, 2006; s. 224–43. [in Russian]
4. Котова О.В., Воробьева О.В. Остеохондроз как причина дорсопатии. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2012; 2: 80–3. / Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Neurology and Rheumatology (Suppl. Consilium Medicum). 2012; 2: 80–3. [in Russian]
5. Трухан Д.И. Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин. Consilium Medicum. 2017; 9: 22–9. / Trukhan D.I. Selection of analgetic with back pain through the prism drug safety and comorbidity: in focus flupirtine. Consilium Medicum. 2017; 9: 22–9. [in Russian]
6. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 5: 821–47.
7. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 10: 1431–8.
8. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs.An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
9. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use AReport of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
10. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
11. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 5: 481–96.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 4: 667–77.
13. Пилипович А.А. Скелетно-мышечные боли: особенности терапии. Новая аптека. 2012; 3 (1): 72–6. / Pilipovich A.A. Skeletno-myshechnye boli: osobennosti terapii. Novaia apteka. 2012; 3 (1): 72–6. [in Russian]
14. Алексеев В.В., Баринов А.Н., Кукушкин М.Л. и др. Боль. Руководство для врачей и студентов. Под ред. Н.Н.Яхно. М.: МЕДпресс-информ, 2009. / Alekseev V.V., Barinov A.N., Kukushkin M.L. i dr. Bol'. Rukovodstvo dlia vrachei i studentov. Pod red. N.N.Iakhno. M.: MEDpress-inform, 2009. [in Russian]
15. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/advisory/COX2.htm
16. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. BMJ 2005; 330: 1370.
17. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751–6.
18. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161–8.
19. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–6.
20. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–11.
21. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308–11.
22. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619–32.
23. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
24. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
25. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005; 365: 475–81.
26. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
27. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9.
28. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
29. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10.
30. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111–5.
31. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–104.
32. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
33. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978–84.
34. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
36. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 9 (1): 4–23. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
37. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901–7.
38. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009; 302: 369–71.
39. Nuesch E, Rutjes AW, Husni E et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009; 4: CD003115.
40. Каратеев А.Е. Что может стать альтернативной нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение? Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2016; 1: 5–12. / Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Neurology and Rheumatology (Suppl. Consilium Medicum). 2016; 1: 5–12. [in Russian]
41. Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in sub-acute/ chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
42. Государственный реестр лекарственных средств. Официальное издание: в 2 т. Т. 2. М.: Медицинский совет, 2009. / Gosudarstvennyi reestr lekarstvennykh sredstv. Ofitsial'noe izdanie: v 2 t. T. 2. M.: Meditsinskii sovet, 2009. [in Russian]
43. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
44. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 12: 157–64.
45. Jakob R, Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
46. Perovich S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
47. Ruppala K, Cao W, Kriegelstein J. Flupirtine protects neurones against ischemic and excitotoxic damage and inhibits the increase ocytosolic Ca2+ concentration. Eur J Pharmacol 1995; 294: 469–73.
48. Gassen M, Pergande G, Youdim ВH. Antioxidant properties of the triaminopyridine, flupirtine. Biochemical Pharmacology 1998; 10: 1323–9.
49. Riethmuller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–6.
50. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
51. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9: 204–12.
52. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 1: 11–8.
53. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 7: 496–502.
54. Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине. Лечение нервных болезней. 2005; 3: 12–7. / Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 3: 12–7. [in Russian]
55. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией. Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 11: 46–8. / Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 11: 46–8. [in Russian]
56. Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней части спины. Врач. 2007; 5: 56–9. / Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
57. Алексеев В.В., Рачин А.П., Подчуфарова Е.В. Флупиртин (Катадолон) – нестандартный подход в терапии боли. Неврология. 2009; 2: 50–3. / Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrologiia. 2009; 2: 50–3. [in Russian]
58. Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой боли в спине. Managepain. 2013; 1: 44–8. / Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
59. Worz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
60. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
61. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 12: 3523–30.
62. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallelgroup phase IV study. Curr Med Res Opin 2012; 10: 1617–34.
63. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
64. Friedel НА, Fitton A. Flupirtine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993; 45: 548–69.
65. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
66. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Flupirtinecontaining_medicines/ European_Commission_final_decision/ WC500155310.pdf
67. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
68. Worz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
69. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
70. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 9: 1495–500.
71. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of acion of flupirtine. J Clin Pharm Ther 2012; 1: 4–6.
72. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 10: 867–81.
2. Pilipovich A.A. Bolit spina – izmeni zhizn'! Novaia apteka. 2012; 11: 108–10. [in Russian]
3. Izbrannye lektsii po nevrologii. Pod red. V.L.Golubeva. M.: Eidos Media, 2006; s. 224–43. [in Russian]
4. Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Neurology and Rheumatology (Suppl. Consilium Medicum). 2012; 2: 80–3. [in Russian]
5. Trukhan D.I. Selection of analgetic with back pain through the prism drug safety and comorbidity: in focus flupirtine. Consilium Medicum. 2017; 9: 22–9. [in Russian]
6. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 5: 821–47.
7. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 10: 1431–8.
8. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs.An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
9. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use AReport of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
10. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
11. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 5: 481–96.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 4: 667–77.
13. Pilipovich A.A. Skeletno-myshechnye boli: osobennosti terapii. Novaia apteka. 2012; 3 (1): 72–6. [in Russian]
14. Alekseev V.V., Barinov A.N., Kukushkin M.L. i dr. Bol'. Rukovodstvo dlia vrachei i studentov. Pod red. N.N.Iakhno. M.: MEDpress-inform, 2009. [in Russian]
15. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/advisory/COX2.htm
16. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. BMJ 2005; 330: 1370.
17. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751–6.
18. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161–8.
19. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–6.
20. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–11.
21. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308–11.
22. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619–32.
23. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
24. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
25. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005; 365: 475–81.
26. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
27. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9.
28. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
29. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10.
30. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111–5.
31. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–104.
32. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
33. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978–84.
34. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
36. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
37. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901–7.
38. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009; 302: 369–71.
39. Nuesch E, Rutjes AW, Husni E et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009; 4: CD003115.
40. Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Neurology and Rheumatology (Suppl. Consilium Medicum). 2016; 1: 5–12. [in Russian]
41. Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in sub-acute/ chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
42.Gosudarstvennyi reestr lekarstvennykh sredstv. Ofitsial'noe izdanie: v 2 t. T. 2. M.: Meditsinskii sovet, 2009. [in Russian]
43. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
44. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 12: 157–64.
45. Jakob R, Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
46. Perovich S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
47. Ruppala K, Cao W, Kriegelstein J. Flupirtine protects neurones against ischemic and excitotoxic damage and inhibits the increase ocytosolic Ca2+ concentration. Eur J Pharmacol 1995; 294: 469–73.
48. Gassen M, Pergande G, Youdim ВH. Antioxidant properties of the triaminopyridine, flupirtine. Biochemical Pharmacology 1998; 10: 1323–9.
49. Riethmuller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–6.
50. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
51. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9: 204–12.
52. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 1: 11–8.
53. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 7: 496–502.
54. Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 3: 12–7. [in Russian]
55. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 11: 46–8. [in Russian]
56. Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
57. Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrologiia. 2009; 2: 50–3. [in Russian]
58. Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
59. Worz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
60. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
61. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 12: 3523–30.
62. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallelgroup phase IV study. Curr Med Res Opin 2012; 10: 1617–34.
63. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
64. Friedel НА, Fitton A. Flupirtine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993; 45: 548–69.
65. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
66. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Flupirtinecontaining_medicines/ European_Commission_final_decision/ WC500155310.pdf
67. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
68. Worz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
69. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
70. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 9: 1495–500.
71. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of acion of flupirtine. J Clin Pharm Ther 2012; 1: 4–6.
72. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 10: 867–81.
2. Пилипович А.А. Болит спина – измени жизнь! Новая аптека. 2012; 11: 108–10. / Pilipovich A.A. Bolit spina – izmeni zhizn'! Novaia apteka. 2012; 11: 108–10. [in Russian]
3. Избранные лекции по неврологии. Под ред. В.Л.Голубева. М.: Эйдос Медиа, 2006; с. 224–43. / Izbrannye lektsii po nevrologii. Pod red. V.L.Golubeva. M.: Eidos Media, 2006; s. 224–43. [in Russian]
4. Котова О.В., Воробьева О.В. Остеохондроз как причина дорсопатии. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2012; 2: 80–3. / Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Neurology and Rheumatology (Suppl. Consilium Medicum). 2012; 2: 80–3. [in Russian]
5. Трухан Д.И. Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин. Consilium Medicum. 2017; 9: 22–9. / Trukhan D.I. Selection of analgetic with back pain through the prism drug safety and comorbidity: in focus flupirtine. Consilium Medicum. 2017; 9: 22–9. [in Russian]
6. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 5: 821–47.
7. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 10: 1431–8.
8. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs.An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
9. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use AReport of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
10. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
11. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 5: 481–96.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 4: 667–77.
13. Пилипович А.А. Скелетно-мышечные боли: особенности терапии. Новая аптека. 2012; 3 (1): 72–6. / Pilipovich A.A. Skeletno-myshechnye boli: osobennosti terapii. Novaia apteka. 2012; 3 (1): 72–6. [in Russian]
14. Алексеев В.В., Баринов А.Н., Кукушкин М.Л. и др. Боль. Руководство для врачей и студентов. Под ред. Н.Н.Яхно. М.: МЕДпресс-информ, 2009. / Alekseev V.V., Barinov A.N., Kukushkin M.L. i dr. Bol'. Rukovodstvo dlia vrachei i studentov. Pod red. N.N.Iakhno. M.: MEDpress-inform, 2009. [in Russian]
15. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/advisory/COX2.htm
16. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. BMJ 2005; 330: 1370.
17. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751–6.
18. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161–8.
19. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–6.
20. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–11.
21. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308–11.
22. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619–32.
23. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
24. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
25. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005; 365: 475–81.
26. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
27. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9.
28. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
29. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10.
30. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111–5.
31. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–104.
32. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
33. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978–84.
34. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
36. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 9 (1): 4–23. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
37. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901–7.
38. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009; 302: 369–71.
39. Nuesch E, Rutjes AW, Husni E et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009; 4: CD003115.
40. Каратеев А.Е. Что может стать альтернативной нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение? Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2016; 1: 5–12. / Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Neurology and Rheumatology (Suppl. Consilium Medicum). 2016; 1: 5–12. [in Russian]
41. Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in sub-acute/ chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
42. Государственный реестр лекарственных средств. Официальное издание: в 2 т. Т. 2. М.: Медицинский совет, 2009. / Gosudarstvennyi reestr lekarstvennykh sredstv. Ofitsial'noe izdanie: v 2 t. T. 2. M.: Meditsinskii sovet, 2009. [in Russian]
43. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
44. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 12: 157–64.
45. Jakob R, Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
46. Perovich S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
47. Ruppala K, Cao W, Kriegelstein J. Flupirtine protects neurones against ischemic and excitotoxic damage and inhibits the increase ocytosolic Ca2+ concentration. Eur J Pharmacol 1995; 294: 469–73.
48. Gassen M, Pergande G, Youdim ВH. Antioxidant properties of the triaminopyridine, flupirtine. Biochemical Pharmacology 1998; 10: 1323–9.
49. Riethmuller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–6.
50. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
51. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9: 204–12.
52. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 1: 11–8.
53. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 7: 496–502.
54. Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине. Лечение нервных болезней. 2005; 3: 12–7. / Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 3: 12–7. [in Russian]
55. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией. Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 11: 46–8. / Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 11: 46–8. [in Russian]
56. Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней части спины. Врач. 2007; 5: 56–9. / Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
57. Алексеев В.В., Рачин А.П., Подчуфарова Е.В. Флупиртин (Катадолон) – нестандартный подход в терапии боли. Неврология. 2009; 2: 50–3. / Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrologiia. 2009; 2: 50–3. [in Russian]
58. Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой боли в спине. Managepain. 2013; 1: 44–8. / Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
59. Worz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
60. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
61. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 12: 3523–30.
62. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallelgroup phase IV study. Curr Med Res Opin 2012; 10: 1617–34.
63. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
64. Friedel НА, Fitton A. Flupirtine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993; 45: 548–69.
65. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
66. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Flupirtinecontaining_medicines/ European_Commission_final_decision/ WC500155310.pdf
67. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
68. Worz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
69. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
70. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 9: 1495–500.
71. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of acion of flupirtine. J Clin Pharm Ther 2012; 1: 4–6.
72. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 10: 867–81.
________________________________________________
2. Pilipovich A.A. Bolit spina – izmeni zhizn'! Novaia apteka. 2012; 11: 108–10. [in Russian]
3. Izbrannye lektsii po nevrologii. Pod red. V.L.Golubeva. M.: Eidos Media, 2006; s. 224–43. [in Russian]
4. Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Neurology and Rheumatology (Suppl. Consilium Medicum). 2012; 2: 80–3. [in Russian]
5. Trukhan D.I. Selection of analgetic with back pain through the prism drug safety and comorbidity: in focus flupirtine. Consilium Medicum. 2017; 9: 22–9. [in Russian]
6. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 5: 821–47.
7. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 10: 1431–8.
8. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs.An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
9. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use AReport of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
10. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
11. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 5: 481–96.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 4: 667–77.
13. Pilipovich A.A. Skeletno-myshechnye boli: osobennosti terapii. Novaia apteka. 2012; 3 (1): 72–6. [in Russian]
14. Alekseev V.V., Barinov A.N., Kukushkin M.L. i dr. Bol'. Rukovodstvo dlia vrachei i studentov. Pod red. N.N.Iakhno. M.: MEDpress-inform, 2009. [in Russian]
15. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/advisory/COX2.htm
16. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. BMJ 2005; 330: 1370.
17. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751–6.
18. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161–8.
19. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–6.
20. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–11.
21. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308–11.
22. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619–32.
23. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
24. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
25. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005; 365: 475–81.
26. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
27. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9.
28. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
29. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10.
30. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111–5.
31. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–104.
32. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
33. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978–84.
34. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
36. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
37. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901–7.
38. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009; 302: 369–71.
39. Nuesch E, Rutjes AW, Husni E et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009; 4: CD003115.
40. Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Neurology and Rheumatology (Suppl. Consilium Medicum). 2016; 1: 5–12. [in Russian]
41. Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in sub-acute/ chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
42.Gosudarstvennyi reestr lekarstvennykh sredstv. Ofitsial'noe izdanie: v 2 t. T. 2. M.: Meditsinskii sovet, 2009. [in Russian]
43. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
44. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 12: 157–64.
45. Jakob R, Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
46. Perovich S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
47. Ruppala K, Cao W, Kriegelstein J. Flupirtine protects neurones against ischemic and excitotoxic damage and inhibits the increase ocytosolic Ca2+ concentration. Eur J Pharmacol 1995; 294: 469–73.
48. Gassen M, Pergande G, Youdim ВH. Antioxidant properties of the triaminopyridine, flupirtine. Biochemical Pharmacology 1998; 10: 1323–9.
49. Riethmuller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–6.
50. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
51. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9: 204–12.
52. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 1: 11–8.
53. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 7: 496–502.
54. Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 3: 12–7. [in Russian]
55. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 11: 46–8. [in Russian]
56. Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
57. Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrologiia. 2009; 2: 50–3. [in Russian]
58. Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
59. Worz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
60. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013; 3: 251–8.
61. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 12: 3523–30.
62. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallelgroup phase IV study. Curr Med Res Opin 2012; 10: 1617–34.
63. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
64. Friedel НА, Fitton A. Flupirtine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993; 45: 548–69.
65. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
66. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Flupirtinecontaining_medicines/ European_Commission_final_decision/ WC500155310.pdf
67. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
68. Worz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
69. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
70. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 9: 1495–500.
71. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of acion of flupirtine. J Clin Pharm Ther 2012; 1: 4–6.
72. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 10: 867–81.
Авторы
А.А.Пилипович
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
aapilipovich@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
aapilipovich@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
aapilipovich@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
aapilipovich@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.